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Abstract
For over 15 years, human subcutaneous adipose tissue has been recognized as a rich
source of tissue resident mesenchymal stem/stromal cells (MSC). The isolation of perivas-
cular progenitor cells from human adipose tissue by a cell sorting strategy was first pub-
lished in 2008. Since this time, the interest in using pericytes and related perivascular stem/
stromal cell (PSC) populations for tissue engineering has significantly increased. Here, we
describe a set of experiments identifying, isolating and characterizing PSC from canine tis-
sue (N = 12 canine adipose tissue samples). Results showed that the same antibodies used
for human PSC identification and isolation are cross-reactive with canine tissue (CD45,
CD146, CD34). Like their human correlate, canine PSC demonstrate characteristics of
MSC including cell surface marker expression, colony forming unit-fibroblast (CFU-F) inclu-
sion, and osteogenic differentiation potential. As well, canine PSC respond to osteoinductive
signals in a similar fashion as do human PSC, such as the secreted differentiation factor
NEL-Like Molecule-1 (NELL-1). Nevertheless, important differences exist between human
and canine PSC, including differences in baseline osteogenic potential. In summary, canine
PSC represent a multipotent mesenchymogenic cell source for future translational efforts in
tissue engineering.
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Introduction
Mesenchymal stem/stromal cells (MSC) are a multipotent cell population with multiple
applications in bone tissue engineering, including promotion of wound repair[1] and tissue
regeneration[2]. Bone marrow and adipose tissue are the two major tissue sources of MSC
most studied for bone tissue regeneration. However, culture-derived MSC from both tissues
are accompanied by significant drawbacks for bone tissue engineering. Bone marrow mesen-
chymal stem/stromal cells (BMSC) come with significant impediments for clinical transla-
tion, including low stem cell frequency, harvest site morbidity, and requirement for culture
derivation. In contrast, adipose tissue is abundant, accessible and readily available by routine
liposuction procedures with minimal donor site morbidity[3–5]. Unfortunately, the cellular
heterogeneity of the stromal vascular fraction (SVF) of adipose tissue is associated with
reduced or unreliable bone forming efficacy[6, 7].
Perivascular stem/stromal cells (PSC) are a homogeneous MSC population purified by fluo-
rescence activated cell sorting (FACS), that can be used for regenerative medicine applications
without culture expansion[8, 9]. They are abundant in human white adipose tissue and are
present in clinically relevant numbers (approximately 40% of the viable human SVF)[10]. PSC
originate in the vessel wall[11, 12] and are composed of two distinct yet related cell popula-
tions, including pericytes (CD34-CD146+CD45-) and adventitial cells (CD34+CD146-CD45-)
[12, 13]. Importantly, PSC are robustly osteogenic in culture and in vivo, migrate actively,
stimulate angiogenesis and secrete diverse growth and differentiation factors (GDFs) to a
greater degree than traditionally derived MSC[12, 14]. Compared with unpurified cells of the
SVF, PSC have shown a significantly increased ability to form bone in several in vivo models
[10, 15]. Moreover, PSC have been shown to promote in vivo bone regeneration across multi-
ple small animal models, including a mouse critical-sized calvarial defect model[8], and a rat
lumbar spinal fusion model[16, 17].
The commitment of MSC to an osteogenic cell fate relies on many signaling pathways and
transcription factors, including: Hedgehog signaling[18–20], β-catenin dependent Wnt signal-
ing, β-catenin independent or non-canonical Wnt signaling,[21–23] and NEL-Like Molecule-
1 (NELL-1) signaling[20, 24], among others. NELL-1 is a secreted osteoinductive protein that
has been studied for its ability to promote osteogenic differentiation in a relatively bone-
specific manner[25–29]. NELL-1 is known to bind to the cell surface receptor Integrin β1,
resulting in focal adhesion kinase (FAK) phosphorylation[30] and a cascade of intracellular
signaling events that regulates the activity of Runt-related transcription factor-2 (RUNX2)[31].
NELL-1 protein has been previously observed to enhance the osteogenic differentiation of
human PSC in vitro, as well as increase PSC-mediated bone formation in vivo[10]. The applica-
tion of PSC with an osteoinductive protein such as NELL-1 may be an effective future combi-
nation therapy for local bone repair.
In prior studies, immunocompromised small animal models have allowed us to examine
the in vivo bone forming potential of human PSC. In order to translate purified perivascular
cell therapies into a clinical possibility, we next sought to translate these findings to a large ani-
mal model. Use of human PSC in a large animal would require use of immunomodulatory
drugs that inhibit tissue repair. Thus, in the current project we sought to purify and validate
the use of large animal (canine) PSC from subcutaneous adipose tissue.
The dog has several unique advantages over other model organisms. Aside from humans,
canines are the most extensively studied species in medicine[32]. The recent sequencing of the
canine genome[33] has revealed significant homology between human and canine genes,
many of which are affected in naturally occurring diseases shared by the two species[34]. In
the context of bone disorders, canines naturally suffer bone related diseases which develop
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similar to those in humans[35]. Thus, canines have been utilized as a translational model in a
wide range of bone pathology and regeneration studies, including limb-sparing orthopaedic
reconstruction[36] and distraction osteogenesis[37]. Of particular interest to the field of bone
tissue engineering, models have been well-described in canine using adipose derived stem/
stromal cells (ASC) for the treatment of cranial defects[38], segmental bone defects[39], radial
and ulnar nonunion fractures[40], and osteoarthritis[41, 42]. Therefore, we investigated the
potential of canine PSC as a prospective cell population for translational bone regeneration
applications. Our study revealed predominant similarities between canine and human PSC,
thus paving the way for use of canine PSC for in vivo efforts in bone tissue engineering.
Materials and methods
PSC identification, isolation and culture
Canine adipose tissue was obtained under IACUC approval from 12 mongrel, adult research
animals of mixed gender (University of California, Los Angeles). Unless otherwise stated, sub-
cutaneous tissue from the dorsum of the animal was used.
In order to test the cross reactivity of human antibodies with canine tissue, immunofluores-
cent detection of markers of pericytes (CD146; AbD Serotec, Raleigh, NC), adventitial cells
(CD34, BD Biosciences, San Jose, CA), and endothelium (CD31, Abcam, Cambridge, MA)
was performed on frozen sections of canine tissue. Canine adipose tissue was snap frozen and
cryosections were obtained at -30˚C. Sections were fixed in a solution of 1:1 methanol:acetone
for 10 minutes at room temperature prior to immunofluorescent staining. Incubation was
done at 1:100 for all antibodies at 4˚C overnight. Images were captured using a Zeiss LSM 780
Confocal microscope (with Fluorescence Correlation Spectroscopy) using a 40 × or 63 × objec-
tive oil immersion lens. Next, PSC were analyzed and isolated from canine adipose tissue via
flow cytometry and fluorescence activated cell sorting (FACS). Isolation and culture were per-
formed as previously described for human PSC isolation[8, 9]. Lipoaspirate specimens were
enzymatically digested to obtain the stromal vascular fraction (SVF). Next, SVF was incubated
with antibodies recognizing CD146 (1:100, AbD Serotec, Raleigh, NC), CD45 (1:100), and
CD34 (1:100) (BD Biosciences, San Jose, CA). The viability dye DAPI (1:1,000, Invitrogen,
Carlsbad, CA) was also added prior to sorting. Cells were sorted using a special order five-laser
BD Aria II high-speed cell sorter (BD Biosciences). Non-viable and hematopoietic cells were
then excluded based on staining for DAPI and CD45, respectively. CD34+CD146- adventitial
cells and CD146+CD34- pericytes were collected as PSC. Flow cytometry of purified samples
was performed for the MSC markers CD44 and CD90 (BD Biosciences). Samples with detect-
able pericyte and adventitial populations were examined. Unless otherwise stated, cells were
cultured in DMEM + 10% Fetal Bovine Serum (FBS) + 1% Penicillin/Streptomycin and
medium was changed routinely every 3 days. N = 12 samples were examined. N = 9 human
PSC samples were examined as a interspecies comparison, with tissues obtained under IRB
approval.
In vitro osteogenic differentiation assays
For osteogenic differentiation, cells were seeded onto 24-well plates at a density of 5x104 cells/
well. After attachment, cells were treated with osteogenic differentiation medium (ODM) con-
sisting of DMEM, 10% FBS, 10 mM β-glycerophosphate and 50 μM ascorbic acid. In select
studies, ODM was supplemented with dexamethasone (1 μM or 100 nM) or recombinant
human NELL-1 (rhNELL-1, 0–1200 ng/ml) (Aragen Bioscience). The medium was refreshed
every three days. After 14 days, osteogenic differentiation was assessed using alkaline phospha-
tase (ALP) staining, quantifications were normalized to total protein content[43]. Alizarin red
Canine perivascular stem cells
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(AR) staining and quantification was performed at 30 days according to manufacturer’s proto-
col (Millipore, Billerica, MA).
Recombinant human NELL-1 was produced by Aragen Bioscience. Briefly, rhNELL-1 was
produced by a genetically modified, DHFR-deficient CHO cell line. A series of CHO cell lines
expressing rhNELL-1 were developed using classical DHFR gene amplification technology.
After selection, in excess of 2,000 subclones were screened using a NELL-1 ELISA assay. From
this screen, 12 clones were selected for expansion. Three clones that were observed to express
the best were identified, and were used for all subsequent rhNELL-1 production.
Quantitative real-time polymerase chain reaction (qRT-PCR)
Quantitative real-time polymerase chain reaction (qRT-PCR) reactions were run using the
CFX96 Real-Time PCR detection system (Bio-Rad). Reactions were incubated in 96-well opti-
cal plates at 95˚C for 10 minutes, followed by 40 cycles at 95˚C for 15 s, and at 60˚C for 60 s.
The threshold cycle (Ct) data were determined using default threshold settings. The Ct was
defined as the fractional cycle number at which the fluorescence passes the fixed threshold.
Reactions were run in duplicate to triplicate per RNA isolate. Primer sequences are shown in
S1 Table.
Colony forming unit-fibroblast (CFU-F) assay
Cells were cultured and plated in six well plates at densities of 250, 500 and 1000 cells/well in
standard growth medium. After 14 days, the number of colonies was measured and quantified
after staining with Giemsa. Experiments were run in duplicates.
Colony forming unit-osteoblast (CFU-OB) assay
Cells were seeded at a density of 250, 500 and 1000 cells/well in six-well plates and grown in
standard growth medium. After attachment, medium was changed to osteogenic differentia-
tion medium (ODM). ODM was constituted with 10 mM β-glycerophosphate and 50 μM
ascorbic acid in DMEM + 10% FBS. After 14 days, the number of osteoblastic colonies was
measured and quantified after ALP staining as previously described[10]. Experiments were
run in duplicates.
Trophic factor secretion
Canine PSC were seeded at 80% confluency in DMEM containing 10% FBS. After attachment,
medium was changed to DMEM with 1% FBS and supplemented with NELL-1. Supernatant
was harvested after 72 hours and Enzyme-linked immunosorbent assays (ELISA) for vascular
endothelial growth factor (VEGF), platelet derived growth factor (PDGF), and fibroblastic
growth factor-2 (FGF-2) were performed per the manufacturer’s instructions (BIOTANG,
Waltham, MA). Experiments were run in duplicates.
Statistical analysis
All results were expressed as mean ± standard error. Statistical analyses were performed using
the SPSS16.0 software. All data were normally distributed. Student’s t test was used for two-
group comparisons, and one-way ANOVA test was used for comparisons of 3 or more groups,
followed by Tukey’s post hoc test. Differences were considered significant with P< 0.05.
Canine perivascular stem cells
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Ethics statement
All research animals were handled according to the guidelines of the Chancellor’s Animal
Research Committee for Protection of Research Subjects at the University of California, Los
Angeles.
Results
Canine and human PSC are obtained by identical processes
Previous studies have optimized the procedure for human PSC isolation[8, 9]. We sought to
translate this protocol to canine tissues. First the cross reactivity and specificity of antibodies
directed against human CD146 and CD34 were examined in canine adipose tissue (Fig 1).
Results showed that previously used antibodies were cross reactive against canine PSC, includ-
ing CD146 (Fig 1A) and CD34 (Fig 1B). Next, canine SVF was collected from enzymatically
digested lipoaspirate. After the exclusion of DAPI+ dead cells and CD45+ hematopoietic cells,
the detection of adventitial cells and pericytes was performed based on the differential expres-
sion of CD34 and CD146 (Fig 1D)[8, 9]. CD34+CD146− adventitial cells and CD146+CD34
− pericytes were isolated by FACS in an identical manner to those derived from human adi-
pose tissue, collectively referred to as PSC. We observed canine pericytes (Fig 1E) and adventi-
tial cells (Fig 1F) to demonstrate positive expression of the MSC markers CD44 and CD90[44].
In comparison, the ‘non-PSC’ cell constituent showed rare CD44 and CD90 expression
(Fig 1G).
Fig 1. Canine PSC in situ identification. Marker expression and isolation by fluorescence activated cell sorting (FACS). (A)
Canine adipose tissue stained with pericytes marker CD146 (green), endothelial marker CD31 (red) (63×), and (B) adventitial cell
marker, CD34 (red), CD146 (green) (40×). DAPI nuclear counterstain appears blue. (C) Cell size. (D) Purified PSC consist of distinct
CD34−CD146+ pericytes and CD34+CD146− adventitial cells. (E) CD146+CD34- pericytes and (F) CD146-CD34+ adventitial cells
express characteristic MSC markers, including CD44 and CD90. In comparison, (G) CD146-CD34- “non-PSC” are predominantly
negative for CD44 and CD90. Scale bar: 25 uM.
https://doi.org/10.1371/journal.pone.0177308.g001
Canine perivascular stem cells
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PSC are abundant in canine white adipose tissue
In order to obtain canine SVF, lipoaspirate was retrieved from twelve canine samples
(Table 1). On average, cell viability of canine SVF was 65.7%, ranging from 30.2% to 93.6%.
From this population, cells were further fractionated by FACS as adventitial cells and pericytes
and collected together as PSC. On average, adventitial cells and pericytes comprised 20.1% and
9.7% of viable SVF, respectively. The composition of adventitial cells within SVF ranged from
6.4% to 39.8%, while pericytes were generally found in lower numbers, ranging from 2.1% to
18.8%. Total PSC therefore comprised on average 30.0% of viable SVF, ranging from 14.3% to
41.3%.
We next sought to determine how SVF yield or viability affected parameters of PSC harvest.
Scatter plots with linear fit trendlines revealed little or no correlation across all parameters
examined (Fig 2). Specifically, a vague and weak negative correlation (R2 = 0.38965) between
the total SVF isolate and the percentage of viable SVF was observed (Fig 2A). Total yield of
SVF isolate was then compared with PSC yield by cell type (Fig 2B–2D). The percentage of
pericytes showed a weak negative correlation with total SVF numbers (R2 = 0.42177) (Fig 2B).
In contrast, the percentage of adventitial cells demonstrated a vague and weak positive correla-
tion with total SVF numbers (R2 = 0.38965) (Fig 2C). Thus, the total PSC population had no
clear linear relationship with total SVF numbers (R2 = 0.15431) (Fig 2D).
Canine PSC demonstrate MSC characteristics
Canine PSC were next evaluated based on their ability to form clonal fibroblastic colonies at
low seeding densities. As expected, PSC formed more total fibroblastic colonies as seeding
densities increased. 250 cells, 500 cells, and 1,000 cells were able to form an average of 19, 25,
and 32 colonies, respectively (Fig 3A). At higher density, colonies began to merge with one
another, preventing an accurate colony count. In order to measure the ability of PSC to form
osteoblastic colonies in vitro, cells were cultured with supplemental osteogenic factors ascorbic
acid and β-glycerophosphate. Canine PSC readily formed osteoblastic colonies when seeded at
a density of 1,000 cells/well (Fig 3B). This was observed by the formation of 0.13, 0.25, and 9
colonies on average by 250 cells, 500 cells, and 1,000 cells, respectively. Thus, like human PSC,
canine PSC have MSC characteristics including the ability to form fibroblastic and osteoblastic
colonies.
Table 1. Yield and frequency of PSC from canine adipose tissue.
Samples SVF (million) Viable SVF (%) Adventitial (%) Pericytes (%) PSC (%)
1 4.5 62.0 14.7 6.9 21.6
2 1.0 63.2 17.7 11.2 28.9
3 24.0 93.6 21.4 9.9 31.3
4 16.6 64.0 29.5 8.0 37.5
5 6.2 76.9 8.5 18.1 26.6
6 8.4 84.0 24.1 14.2 38.3
7 20.0 30.2 6.4 7.9 14.3
8 12.6 62.7 11.6 12.5 24.1
9 50.0 61.5 39.8 1.5 41.3
10 24.8 65.7 9.3 18.8 28.1
11 57.6 55.3 24.2 5.7 29.9
12 60.0 69.2 33.8 2.1 35.9
Average ± SEM 23.8 ± 6.0 65.7 ± 4.5 20.1 ± 3.1 9.7 ± 1.6 30.0 ± 2.2
https://doi.org/10.1371/journal.pone.0177308.t001
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NELL-1 enhances canine PSC osteogenic differentiation
The effects of different contents of osteogenic differentiation medium (ODM) on canine PSC
were first assessed, including the addition of two different concentrations of dexamethasone
(S1 Fig). As expected, all ODM types (with or without dexamethasone) increased the osteo-
genic differentiation of PSC in comparison to growth medium control. Overall, dexametha-
sone addition to ODM did not result in a reliable increase in markers of osteogenic
differentiation, although higher concentration dexamethasone significantly increased gene
expression of COL1A1.
Fig 2. Comparison of total SVF to PSC. Each sample is represented by a single data point. Linear fit of total SVF cell yield with
respect to (A) percent viable SVF, (B) percent pericytes, (C) percent adventitial cells, and (D) percent PSC. Trendlines, equations,
and R2 values are shown. Little or no linear correlation was observed across all variables examined.
https://doi.org/10.1371/journal.pone.0177308.g002
Canine perivascular stem cells
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Having observed that Dexamethasone to not reliably influence canine PSC osteogenesis, we
next examined the effects of recombinant NELL-1 protein. In order to examine the osteogenic
effects of the differentiation factor NELL-1 on canine PSC, cells were treated with recombinant
protein in increasing dosages of 300, 600, and 1,200 ng/mL and osteogenic effects were visual-
ized by alkaline phosphatase (ALP) and Alizarin red (AR) staining (Fig 4). ALP activity was
slightly increased by the addition of NELL-1 at concentrations of 300 and 600 ng/mL by 12.1%
and 15.3%, respectively. In contrast, 1,200 ng/mL supplementation of NELL-1 to canine PSC
stimulated a stronger osteogenic response observed by a 55.7% increase in ALP activity (Fig
4A). Similarly, bone nodule deposition quantified by AR staining only increased by 18.6% and
20.1% after the supplementation of 300 ng/mL and 600 ng/mL NELL-1, respectively, while the
addition of 1,200 ng/mL increased bone nodule deposition 284% over the control (Fig 4B).
Osteogenic gene expression among PSC treated with or without NELL-1 was next assayed by
qRT-PCR (Fig 4C and 4D). Expression of the osteogenic markers Alkaline Phosphatase (ALP)
and Bone Sialoprotein (BSP) showed an increase in response to the addition of NELL-1 at all
doses (Fig 4C and 4D), although these effects were not statistically significant with BSP. These
data demonstrate that canine PSC are responsive to the osteoinductive protein NELL-1 in a
dose-dependent fashion.
Fig 3. Canine PSC retain stem cell character following fluorescence activated cell sorting (FACS). Freshly
isolated PSC were seeded at low densities (200, 500, and 1,000 cells/well) in 6 well plates and evaluated for colony
formation after 14 days. (A) Clonal colonies formed by colony forming units-fibroblast (CFU-F) were observed by
giemsa staining and (B) clonal colonies formed by colony forming units-osteoblast (CFU-OB), visualized by ALP
staining after 14 days of osteogenic differentiation are shown. Mean ± SEM of total colony forming units are shown.
*p < 0.05, **p < 0.01 versus 250 cells/ well.
https://doi.org/10.1371/journal.pone.0177308.g003
Canine perivascular stem cells
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NELL-1 enhances canine PSC production of trophic factors VEGF, FGF-
2, and PDGF
PSC, like other MSC types, are hypothesized to exert their effects via both direct osteogenic dif-
ferentiation and paracrine stimulation of osteogenesis and vasculogenesis[45]. In order to eval-
uate the effects of NELL-1 on trophic factor production in canine PSC, enzyme-linked
immunosorbent assays for the angiogenic factors: vascular endothelial growth factor (VEGF),
fibroblast growth factor-2 (FGF-2), and platelet-derived growth factor (PDGF) were used to
detect protein production in response to NELL-1 (300, 600, and 1,200 ng/mL). The production
of VEGF was enhanced by addition of NELL-1 in a dose dependent manner in canine PSC, as
Fig 4. Canine PSC are responsive to the osteoinductive factor NELL-1. Canine PSC were cultured under osteogenic conditions and
treated with varying doses of NELL-1 (0, 300, 600, 1200 ng/mL). Osteogenic differentiation was evaluated by (A) alkaline phosphatase
(ALP) staining and enzyme activity at 5 days and (B) Alizarin Red (AR) staining at 14 days of osteogenic differentiation. Quantification of
the AR stain is based on random n = 3 (40×) images, using the Adobe Photoshop cc 2016 magic wand tool (tolerance = 30). Scale
Bar = 200 μM. Gene expression analysis of osteogenic differentiation markers (C) ALP and (D) BSP was performed after 14 days of
osteogenic differentiation. Mean ± SEM are shown. *p < 0.05, **p < 0.01.
https://doi.org/10.1371/journal.pone.0177308.g004
Canine perivascular stem cells
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the addition of NELL-1 increased the production of VEGF by 33.8% to 320.9% (Fig 5A). Simi-
larly, FGF-2 production was enhanced by the addition of NELL-1. The addition of 1,200 ng/
mL NELL-1 increased FGF-2 production by 369.4% over the control (Fig 5B). PDGF produc-
tion in canine PSC was modestly increased by the addition of NELL-1 up to 37% (Fig 5C). In
summary, NELL-1 induces canine PSC expression of modulate production of osteogenic and
angiogenic growth and differentiation factors.
Discussion
The current study investigates canine PSC as a stem/stromal cell population for translational
efforts in bone tissue engineering. Our data revealed that canine PSC are readily isolated from
SVF in abundant numbers with an identical isolation protocol as human PSC. These data fur-
ther confirm the perivascular location of MSC in mammals, as already described in man[13,
46, 47], mouse[48, 49], sheep[50] and horse (Esteves et al., under review). Remarkably, the
same markers were used to identify PSC in these different species, using in most instances
cross-reactive antibodies. This suggests a highly conserved set of perivascular markers for an
ancestral population of tissue regenerative cells. Additionally, we found that canine PSC
secrete the trophic factors VEGF, FGF-2, and PDGF and are responsive to the novel osteoin-
ductive molecule NELL-1.
Important similarities and differences exist between canine and human PSC. Similarities
between canine and human sources include their MSC properties, ability to undergo osteo-
genic differentiation, and responsiveness to osteoinductive cues like NELL-1[10]. Like human
PSC, canine PSC express MSC markers such as CD44 and CD90, and give rise to clonal fibro-
blastic cell colonies at low densities. Also similar to human PSC, canine PSC were able to form
osteoblastic colonies and undergo the process of osteogenic differentiation / mineralization in
Fig 5. Secretion of trophic factors by canine PSC in response to NELL-1. Secreted (A) vascular endothelial growth factor (VEGF),
(B) fibroblastic growth factor-2 (FGF-2), and (C) platelet derived growth factor (PDGF) in the conditioned medium as assessed by
enzyme-linked immunosorbent assay (ELISA) at 72-h treatment with NELL-1 (300–1,200 ng/mL). Mean ± SEM are shown. *p < 0.05,
**p < 0.01.
https://doi.org/10.1371/journal.pone.0177308.g005
Canine perivascular stem cells
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vitro. Finally, both human and canine cells appear to respond to the pro-osteogenic stimulus
of NELL-1 protein[15].
Despite the similarities between PSC of canine or human origin, differences also exist.
These differences include: relative cell abundance within adipose tissue, and baseline osteo-
genic potential. In our study of twelve samples, canine PSC represent ~30% of canine SVF.
This contrasts with human PSC which represent ~39–41% of human SVF[9, 10]. When these
differences are further examined, it appears that the difference can be attributable to the fre-
quency of adventitial cell subpopulation among canine samples. Pericyte frequency is similar
between species, representing 9.7% and 8% from canine and human SVF, respectively[9].
Adventitial cell frequency appears dissimilar between species, representing 20.1% and 33%
from canine and human SVF[9]. Whether this reflects an underlying difference in the vascu-
larity of canine adipose tissue, a difference in the relative adventitial cell density among larger
vessels, or a difference in antibody affinity based on species is not yet known. A second differ-
ence is relative frequency of MSC markers in dog versus human cells. A relative consensus
exists regarding the minimal criteria for multipotent mesenchymal stem/stromal cells (MSC)
in human cells, as put forth by Dominici et al.[51]. Unfortunately, a similar consensus has not
been reached for canine MSC. However, our results lie in similarity to most prior reports from
other research groups in canine adipose-derived MSC, which by and large report a CD44
+CD90+CD45- cell population as the most consistent markers for canine MSC[52–58].
Another and more striking difference between PSC by species is their baseline osteogenic
potential (S2 Fig). We previously reported that human PSC undergo brisk osteogenic differen-
tiation over the course of two weeks or less in standard osteogenic culture with only ascorbic
acid and β-glycerophosphate supplementation[10]. In contrast, the present study showed that
canine PSC after similar isolation and propagation techniques undergo a much slower process
of osteogenic differentiation, with very sparse bone nodules formed. Only with NELL-1 were
significant bone nodules seen. These results are in agreement with prior comparative findings
across species using unpurified adipose-derived stromal cells (ASC)[59]. In this study, canine
ASC were found to proliferate to a greater degree than human ASC, but had much reduced
osteogenic potential. Canine ASC were also responsive to the pro-osteogenic effects of retinoic
acid supplementation, while human ASC were not[60]. These studies using an unpurified stro-
mal population clearly have overlapping findings with purified, adipose-tissue derived PSC. As
canine PSC are translated into an in vivo model of bone repair, their relatively low baseline
osteogenic potential must be taken into account.
Although efforts in canine PSC isolation and application represent a step forward to clinical
translation of a PSC based product for skeletal regeneration in patients, use of canine tissue
poses several practical concerns that should be addressed. First and foremost, the societal view
of dogs as a pet and human companion prompts use of alternate large animal models. Alterna-
tive large animals that do not have the same societal significance, such as sheep, offer many
similarities in bone structure and composition to human bone[61–64]. Of note, a similar PSC
population has recently been successfully isolated from ovine adipose tissue[50]. Importantly,
PSC isolation has potential translational applicability in both human and veterinary medicine
[65]. The therapeutic applications of PSC may well be beneficial for pets as well as man.
In summary, our data show that canine PSC are abundant in the SVF in clinically relevant
numbers, comprising on average 30% of the viable SVF. Importantly, canine PSC retain MSC
characteristics, and are responsive to osteoinductive stimuli such as NELL-1. Although differ-
ences in baseline osteogenic potential exist between canine and human PSC, use of FACS puri-
fied canine PSC represents a new method to deliver autologous cells in a large animal model of
bone repair to evaluate strategies/tactics to be developed in humans.
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Supporting information
S1 Data. Raw data file.
(XLSX)
S1 Fig. Effects of dexamethasone on osteogenic differentiation of canine PSC. Canine PSC
were cultured under osteogenic conditions and treated with varying doses of dexamethasone
(100 nM or 1 μM). Osteogenic differentiation was evaluated by (A) alkaline phosphatase
(ALP) staining and (B) quantification at 7 days. Quantification of the ALP stain is based on
random n = 10 (40×) images, using the Adobe Photoshop cc 2016 magic wand tool (toler-
ance = 30). Scale bar = 100 μM. Gene expression analysis of osteogenic differentiation markers
(C) ALP (D) COL1A1 and (D) OPN was performed on day 14 by qRT-PCR. Mean ± SEM are
shown. p< 0.05, p< 0.01.
(TIF)
S2 Fig. Differences in human and canine PSC baseline osteogenic potential. Human and
canine PSC were cultured under identical osteogenic conditions and stained by (A) alkaline
phosphatase (ALP) and (B) alizarin red (AR). Quantification of the AR and ALP stains are
based on random n = 4–9 (40×) images, using the Adobe Photoshop cc 2016 magic wand tool
(tolerance = 30). Mean ± SEM are shown. p< 0.05, p< 0.01.
(TIF)
S1 Table. qRT-PCR primers.
(DOCX)
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